[go: up one dir, main page]

MX2009008022A - Metodos y composiciones para tratar neuropatias. - Google Patents

Metodos y composiciones para tratar neuropatias.

Info

Publication number
MX2009008022A
MX2009008022A MX2009008022A MX2009008022A MX2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A
Authority
MX
Mexico
Prior art keywords
methods
activity
compositions
neuropathies
diseased
Prior art date
Application number
MX2009008022A
Other languages
English (en)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2009008022A publication Critical patent/MX2009008022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para tratar o prevenir la degradación axonal en enfermedades neuropáticas y trastornos neurológicos en mamíferos; los métodos pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa, por lo menos en parte, aumentando la actividad sirtuinAMPK, la actividad LKB 1 y/o la actividad CaMKKß en neuronas enfermas y/o lesionadas; los métodos también pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa aumentando la cavidad de NAD en neuronas enfermas y/o lesionadas, solo o en combinación con agentes que actúan por otros mecanismos; también se describen métodos para analizar agentes para el tratamiento de neuropatías y vectores recombinantes para el tratamiento o la prevención de dichas neuropatías.
MX2009008022A 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias. MX2009008022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88685407P 2007-01-26 2007-01-26
PCT/US2008/001085 WO2008091710A2 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
MX2009008022A true MX2009008022A (es) 2009-12-11

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008022A MX2009008022A (es) 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias.

Country Status (5)

Country Link
US (3) US20100047177A1 (es)
EP (1) EP2124985A4 (es)
CA (1) CA2676609A1 (es)
MX (1) MX2009008022A (es)
WO (1) WO2008091710A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5684578B2 (ja) 2008-03-03 2015-03-11 エヌエーディー ライフ プロプライエタリー リミテッド リスベラトロールの医薬製剤、および細胞障害を治療するためのその使用方法
EP2323649A4 (en) * 2008-07-25 2011-09-07 Univ Emory TREATMENT OF VARIOUS DISORDERS WITH 7,8-DIHYDROXY FLAVONE AND ITS DERIVATIVES
BRPI0917626A2 (pt) 2008-12-08 2017-07-11 Univ Northwestern Método para modular atividade do fator 1 de transcrição do choque térmico (hsf1) em uma célula, método para aumentar ou diminuir a atividade de hsf1 em um indivíduo necessitando do mesmo método para tratar um paciente, método para identificar um agente que modula a atividade de hsf1 em uma célula, método para ativar a resposta ao choque térmico em uma célula ou em um paciente necessitando do mesmo e composição farmacêutica
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Ｌｋｂ１活性化剤
EP2579870B1 (en) 2010-06-09 2018-02-14 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
EP2877461B1 (en) 2012-07-27 2018-05-09 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2014146044A1 (en) 2013-03-15 2014-09-18 Washington University Administration of nicotinamide mononucleotide in the treatment of disease
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
MX2016016071A (es) 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
PL3670522T3 (pl) 2014-07-24 2022-02-21 W.R. Grace & Co. - Conn. Krystaliczna postać chlorku rybozydu nikotynamidu
FI3268379T3 (fi) 2015-03-09 2023-12-15 Grace W R & Co Nikotiiniamidiribosidin kiteinen muoto
PL3331894T3 (pl) 2015-08-05 2021-08-23 Metro International Biotech, Llc Pochodne mononukleotydu nikotynamidowego i ich zastosowania
US20170068860A1 (en) * 2015-09-09 2017-03-09 Alex Adekola System for measuring crowd density
GB2542881B (en) * 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017201425A1 (en) * 2016-05-20 2017-11-23 The Trustees Columbia University In The City Of New York Anabolic enhancers for ameliorating neurodegeneration
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
JP2021506898A (ja) 2017-12-22 2021-02-22 エリシウム ヘルス，インコーポレーテッド ニコチンアミドリボシドクロリドの結晶形態
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
CA3127453A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
IT202000007726A1 (it) * 2020-04-10 2021-10-10 Solongevity Nutraceuticals S R L Composizioni mimetiche della restrizione calorica
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
US20250018058A1 (en) * 2021-02-26 2025-01-16 Icahn School Of Medicine At Mount Sinai Method for decreasing degeneration of retinal ganglion cells
CN115212165B (zh) * 2022-08-19 2024-12-03 哈尔滨医科大学 修复神经热损伤的凝胶及其制备方法和应用
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
WO2024170772A1 (en) * 2023-02-17 2024-08-22 Mim Neurosciences Ab Epigallocatechin-3-gallate (egcg) analogs for use in the treatment of diseases in which an increase of nad+ is beneficial such as glaucoma
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途
KR20250056047A (ko) 2023-10-18 2025-04-25 성균관대학교산학협력단 알피넘아이소플라본을 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076691A1 (en) * 1998-04-28 2001-02-21 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
AU5446900A (en) * 1999-05-28 2000-12-18 Immunex Corporation Novel murine and human kinases
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
WO2005004814A2 (en) * 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
CA2548671C (en) * 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2005077091A2 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
US7776326B2 (en) * 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2617557A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
KR101460820B1 (ko) * 2007-01-16 2014-11-11 아이피아이엔티엘, 엘엘씨 대사 증후군의 치료를 위한 신규한 조성물

Also Published As

Publication number Publication date
EP2124985A4 (en) 2011-06-08
US20140011890A1 (en) 2014-01-09
CA2676609A1 (en) 2008-07-31
WO2008091710A2 (en) 2008-07-31
EP2124985A2 (en) 2009-12-02
US20160367497A1 (en) 2016-12-22
WO2008091710A3 (en) 2008-10-09
US20100047177A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
WO2006001982A3 (en) Methods and compositions for treating neuropathies
Close et al. Skeletal muscle damage with exercise and aging
Okunieff et al. Antioxidants reduce consequences of radiation exposure
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
AR063470A1 (es) Terapia combinada
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
WO2005000331A3 (en) Compositions for the treatment and prevention of degenerative joint disorders
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
WO2005060960A3 (en) Use of histamine to treat bone disease
BR112013005439A2 (pt) compostos de quinoxalina
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Legal Events

Date Code Title Description
FA Abandonment or withdrawal